GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (OTCPK:LABFF) » Definitions » Shiller PE Ratio

Laboratorios Farmaceuticos Rovi (Laboratorios Farmaceuticos Rovi) Shiller PE Ratio : 52.79 (As of Jun. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Shiller PE Ratio?

As of today (2024-06-08), Laboratorios Farmaceuticos Rovi's current share price is $86.05. Laboratorios Farmaceuticos Rovi's E10 for the quarter that ended in Mar. 2024 was $1.63. Laboratorios Farmaceuticos Rovi's Shiller PE Ratio for today is 52.79.

The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Shiller PE Ratio or its related term are showing as below:

LABFF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 30.06   Med: 49.46   Max: 105.81
Current: 59.16

During the past years, Laboratorios Farmaceuticos Rovi's highest Shiller PE Ratio was 105.81. The lowest was 30.06. And the median was 49.46.

LABFF's Shiller PE Ratio is ranked worse than
71.43% of 154 companies
in the Biotechnology industry
Industry Median: 30.475 vs LABFF: 59.16

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.317. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $1.63 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Laboratorios Farmaceuticos Rovi Shiller PE Ratio Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Shiller PE Ratio Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.74 69.67 90.47 30.34 40.23

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.07 32.33 36.48 40.23 52.92

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Shiller PE Ratio

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Shiller PE Ratio falls into.



Laboratorios Farmaceuticos Rovi Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Laboratorios Farmaceuticos Rovi's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=86.05/1.63
=52.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Laboratorios Farmaceuticos Rovi's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.317/122.7621*122.7621
=0.317

Current CPI (Mar. 2024) = 122.7621.

Laboratorios Farmaceuticos Rovi Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.246 101.081 0.299
201409 0.127 100.441 0.155
201412 0.106 100.251 0.130
201503 0.140 99.474 0.173
201506 0.162 101.138 0.197
201509 0.067 99.559 0.083
201512 0.073 100.268 0.089
201603 0.212 98.638 0.264
201606 0.196 100.333 0.240
201609 0.080 99.737 0.098
201612 0.098 101.842 0.118
201703 0.138 100.896 0.168
201706 0.214 101.848 0.258
201709 0.031 101.524 0.037
201712 0.005 102.975 0.006
201803 0.171 102.122 0.206
201806 0.017 104.165 0.020
201809 0.192 103.818 0.227
201812 0.046 104.193 0.054
201903 0.141 103.488 0.167
201906 0.189 104.612 0.222
201909 0.289 103.905 0.341
201912 0.172 105.015 0.201
202003 0.278 103.469 0.330
202006 0.319 104.254 0.376
202009 0.366 103.521 0.434
202012 0.313 104.456 0.368
202103 0.512 104.857 0.599
202106 0.591 107.102 0.677
202109 1.017 107.669 1.160
202112 1.116 111.298 1.231
202203 1.084 115.153 1.156
202206 0.546 118.044 0.568
202209 0.789 117.221 0.826
202212 1.581 117.650 1.650
202303 0.970 118.948 1.001
202306 0.390 120.278 0.398
202309 1.051 121.343 1.063
202312 1.084 121.300 1.097
202403 0.317 122.762 0.317

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Laboratorios Farmaceuticos Rovi  (OTCPK:LABFF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Laboratorios Farmaceuticos Rovi Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (Laboratorios Farmaceuticos Rovi) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.